ResMed (RMD) legal chief pre-planned sale: 50 shares at $260

Rhea-AI Filing Summary

ResMed Inc.'s Global General Counsel Michael J. Rider reported a small automatic share sale under a pre-set trading plan. On 02/04/2026, he sold 50 shares of ResMed common stock at $260 per share in a transaction coded as a sale.

After this trade, he beneficially owned 9,691 shares, all reported as directly held. The filing notes that the transaction was conducted under a Rule 10b5-1 plan adopted on February 28, 2025, indicating it was pre-arranged rather than a discretionary market-timed trade.

Insider Trade Summary

Net Seller: 50 shares ($13,000)

Net Sell 1 txn

Insider Rider Michael J

Role Global General Counsel

Sold 50 shs ($13K)

Type	Security	Shares	Price	Value
Sale	ResMed Common Stock	50	$260.00	$13K

Holdings After Transaction: ResMed Common Stock — 9,691 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rider Michael J

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Global General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	02/04/2026		S(1)		50	D	$260	9,691	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025.

	/s/ Michael J. Rider, Global General Counsel and Secretary	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ResMed (RMD) report for Michael J. Rider?

ResMed reported that Global General Counsel Michael J. Rider sold 50 shares of ResMed common stock on February 4, 2026. The sale was reported as a non-derivative transaction at $260 per share under a pre-established Rule 10b5-1 trading plan.

How many ResMed (RMD) shares does Michael J. Rider hold after this Form 4?

After the reported transaction, Michael J. Rider beneficially owned 9,691 shares of ResMed common stock. These shares are reported as held directly, reflecting his position following the February 4, 2026 sale of 50 shares at $260 per share.

At what price were the ResMed (RMD) shares sold in this insider transaction?

The 50 ResMed common shares reported on this Form 4 were sold at $260 per share. The transaction occurred on February 4, 2026 and was coded as a sale, with ownership remaining direct after the trade.

Was the February 4, 2026 ResMed (RMD) insider sale discretionary or under a plan?

The filing states the transaction was conducted under a Rule 10b5-1 plan adopted on February 28, 2025. Such plans pre-schedule trades, indicating the February 4, 2026 sale was executed according to that pre-arranged trading program.

What role does the reporting person hold at ResMed (RMD) in this Form 4?

The reporting person, Michael J. Rider, is identified as ResMed’s Global General Counsel. He is not listed as a director or 10% owner, but as an officer, and this Form 4 reports his personal direct holdings and sale of common stock.

Does the ResMed (RMD) Form 4 involve derivative securities or only common stock?

This Form 4 only reports a transaction in ResMed common stock. Table II for derivative securities is present but contains no reported derivative acquisitions or dispositions, indicating the filing relates solely to a non-derivative common stock sale.